Study: Gleevec may boost efficacy of stroke therapy

06/22/2008 | Reuters

An international team of scientists who induced stroke in mice found that those that received Novartis AG's leukemia drug Gleevec experienced 33% less blood vessel leakage linked to tissue plasminogen activator, a clot-dissolving drug. The findings suggest that Gleevec may help reduce tPA-related adverse events and increase the number of patients who could receive the stroke therapy. The researchers plan to begin human trials of the drug combination in the next few months.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC